Log In
    News

    Avino Silver & Gold Mines (ASM) Scheduled to Present at NobleCon18 Investor Conference

    4/4/2022
    Natural Resources
    0 min read

    Avino President & CEO David Wolfin provides a preview of their upcoming presentation at NobleCon18

    NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

    Free Registration Available – More Info


    News and Advanced Market Data on ASM


    NobleCon18 Presenting Companies

    About Avino

    Avino is primarily a silver producer from its wholly owned Avino Mine near Durango, Mexico. The Company’s silver, gold and copper production remains unhedged. The Company’s mission and strategy is to create shareholder value through its focus on profitable organic growth at the historic Avino Property and the strategic acquisition of mineral exploration and mining properties. We are committed to managing all business activities in a safe, environmentally responsible, and cost-effective manner, while contributing to the well-being of the communities in which we operate. We encourage you to connect with us on Twitter at @Avino and on LinkedIn at Avino Silver & Gold Mines. To view the Avino Mine VRIFY tour, please click here.
    Share
    Related News
    ‌
    Release – Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
    5/23/2025
    Health

    Release – Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

    Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its...
    5 min read
    ‌
    Release – Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
    5/23/2025
    Health

    Release – Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

    Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering of shares of its common stock....
    5 min read
    ‌
    Release – Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
    5/23/2025
    Health

    Release – Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

    Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that its lead compound, Hydronidone (F351), met the primary endpoint in a pivotal Phase...
    7 min read
    ‌
    QuoteMedia Inc. (QMCI) – Delivers Encouraging Q1 Results
    5/23/2025
    Uncategorized

    QuoteMedia Inc. (QMCI) – Delivers Encouraging Q1 Results

    Solid Q1 Results. The company reported Q1 revenue of $4.8 million, which increased 3% over the prior year period, and was in line with our estimate of $4.8 million. Notably, revenue...
    3 min read

    Inbox Intel from Channelchek.

    Informed investors make more money. And it’s all about timing. Get it when it happens.

    By clicking submit you are agreeing to the Terms of Use and Privacy Policy
    Log In